GH - Guardant Health, Inc.

90.36
-0.710   -0.786%

Share volume: 2,470,689
Last Updated: 04-21-2026
Healthcare/Services – Health: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$91.07
-0.71
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
49%
Profitability 43%
Dept financing 43%
Liquidity 73%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
6.36%
3 Months
-22.95%
6 Months
32.82%
1 Year
106.30%
2 Year
109.22%
Key data
Stock price
$90.36
P/E Ratio 
0.00
DAY RANGE
$90.28 - $95.18
EPS 
-$3.32
52 WEEK RANGE
$36.36 - $120.74
52 WEEK CHANGE
$97.98
MARKET CAP 
12.874 B
YIELD 
N/A
SHARES OUTSTANDING 
131.170 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$2,198,781
AVERAGE 30 VOLUME 
$2,203,377
Company detail
CEO: Helmy Eltoukhy
Region: US
Website: guardanthealth.com
Employees: 1,790
IPO year: 2018
Issue type:
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.

Recent news